Sunesis Pharmaceuticals (FRA:RYIS) Interest Expense : €-0.26 Mil (TTM As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sunesis Pharmaceuticals's interest expense for the three months ended in Dec. 2020 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2020 was €-0.26 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sunesis Pharmaceuticals's Operating Income for the three months ended in Dec. 2020 was € -4.68 Mil. Sunesis Pharmaceuticals's Interest Expense for the three months ended in Dec. 2020 was € 0.00 Mil. Sunesis Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Sunesis Pharmaceuticals Interest Expense Historical Data

The historical data trend for Sunesis Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Interest Expense Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Get a 7-Day Free Trial

-1.63

-1.18

-1.01

-0.46

-0.25

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Interest Expense	Get a 7-Day Free Trial															-0.06	-0.06	-0.06	-0.14	-

Sunesis Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.26 Mil.

Sunesis Pharmaceuticals (FRA:RYIS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunesis Pharmaceuticals's Interest Expense for the three months ended in Dec. 2020 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2020 was €-4.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2020 was €0.00 Mil.

Sunesis Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Sunesis Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines